ARCT:NASDAQ
Arcturus Therapeutics Holdings Inc
$13.98
arrow_downward
-5.16%(-0.76) 1D
$13.54
arrow_downward
-3.15% (-0.44)bedtimeAfter hours
Closed: Sep 10, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ARCT...
Open
$14.29
High
$14.33
Low
$13.12
Mkt. cap
397.35M
Avg. vol.
1.21M
Volume
242.00
52-wk high
$24.14
52-wk low
$5.50
EPS
-$3.31
Beta
2.48
Shares outstanding
28.42M
No. of employees
109
Open
$14.29
High
$14.33
Low
$13.12
Mkt. cap
397.35M
Avg. vol.
1.21M
Volume
242.00
52-wk high
$24.14
52-wk low
$5.50
EPS
-$3.31
Beta
2.48
Shares outstanding
28.42M
No. of employees
109
News stories
From web sources and news partners
Investing.com Canada
·
19 hours ago
Arcturus Therapeutics at cantoral global healthcare conference: data catalysts ahead
Profile
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
About Arcturus Therapeutics Holdings Inc